{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Rate of MRD negativity at a sensitivity of 10\\^-5 was defined as the percentage of participants who achieved MRD negative status in the MRD-evaluable analysis set.","groups":[{"description":"Participants received 80 mg modakafusp alfa, infusion IV, once on Day 1, Q4W, in combination with 10 mg lenalidomide capsules orally once daily continuously on Days 1 to 28, in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or to a maximum of 2 years for MRD \\[-\\] negative participants, whichever occurred first.","id":"OG000","title":"Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg"}],"populationDescription":"MRD data was not collected as no participant achieved the criteria for MRD-evaluable analysis set (i.e., being on study at 6 months).","reportingStatus":"POSTED","timeFrame":"At 6 months, 1 year, and 2 years after the start of treatment","title":"Group 1: Percentage of Participants With MRD Negativity Status at a Threshold of 10^-5","type":"SECONDARY"}